⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026572 | 0.78 | ALDH1A1 (0.48) | — | |
| SCHEMBL454402 | 0.77 | ALDH1A1 (0.43) | — | |
| SCHEMBL31172969 | 0.75 | GRM5 (0.54) | — | |
| SCHEMBL995794 | 0.75 | GRM5 (0.54) | — | |
| SCHEMBL20270120 | 0.73 | GRM5 (0.47) | — | |
| SCHEMBL12804631 | 0.73 | ALDH1A1 (0.43) | — | |
| SCHEMBL22027752 | 0.72 | — | — | |
| SCHEMBL75830 | 0.71 | — | — | |
| SCHEMBL239071 | 0.71 | — | — | |
| SCHEMBL3980794 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119563-B2 | N-substituted azacycles | FMC CORPORATION (US) | 2012-02-21 | — | — | US | claimed |
| US-20090215821-A1 | N-Substituted Azacycles | FMC CORPORATION | 2009-08-27 | — | — | US | claimed |
| EP-1673083-A4 | N-SUBSTITUTED AZACYCLES | BAYER CROPSCIENCE AG (DE) | 2008-12-17 | — | — | EP | claimed |
| EP-1673083-A2 | N-SUBSTITUTED AZACYCLES | FMC CORPORATION (US) | 2006-06-28 | — | — | EP | claimed |
| WO-2005036961-A2 | N-SUBSTITUTED AZACYCLES | FMC CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230338344-A1 | AMPK Activators and Methods of Use Thereof | BIOVERATIV THERAPEUTICS INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4221700-A1 | AMPK ACTIVATORS AND METHODS OF USE THEREOF | Bioverativ Therapeutics Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3861001-A1 | BORON CONTAINING PDE4 INHIBITORS | Pfizer Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PFIZER INC. (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1572207-A1 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL) PIPERIDINES AND PYRIDINES | FMC CORPORATION (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | XIN ZHILI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005036961-A2 | N-SUBSTITUTED AZACYCLES | FMC CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
| WO-2004060371-A1 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL) PIPERIDINES AND PYRIDINES | FMC CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |